Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | FECH | P22830 | 1/20 | 0.46 |
| ▸ | CLK3 | P49761 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12680348 | 0.91 | PLK1 (0.46) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680319 | 0.90 | PLK1 (0.45) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680322 | 0.89 | PLK1 (0.43) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680352 | 0.87 | PLK1 (0.62) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680343 | 0.86 | PLK1 (0.57) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680345 | 0.86 | PLK1 (0.54) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12681479 | 0.86 | PLK1 (0.54) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12681471 | 0.84 | PLK1 (0.40) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680325 | 0.84 | PLK1 (0.43) | PLK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL12680336 | 0.84 | PLK1 (0.48) | PLK1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273787-B2 | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions | ONCONOVA THERAPEUTICS, INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273787-B2 | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions | ONCONOVA THERAPEUTICS, INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC (US) | 2010-01-28 | — | — | US | disclosed |
| WO-2008033475-A2 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | CD40, TNFRSF9, NGFR | PLK1 297/4885HDAC3 4016/4885HDAC4 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.